Caught Out By Dis Chem Pharmacies' Slide? Here's What The Bears Saw

Revenue at Dis-Chem Pharmacies moved up while profit margins thinned, an awkward mix for anyone who thought better trading would mean a stronger portfolio. For Dis-Chem Pharmacies shareholders, the loss from the start of the year was 22.5%, including dividends. If you had been weighing a purchase on 1 January 2026, with bulls arguing for aggressive expansion and bears warning about rising costs, which signals in the published numbers would you have focused on?

The easy part of this move is behind Dis-Chem Pharmacies. Zero in on 200 high quality undervalued stocks for companies trading below our estimates.

The Two Stories Investors Were Weighing On Dis-Chem Pharmacies

The shares cost ZAR35 at the start of the period, and anyone looking at Dis-Chem Pharmacies then had to choose between two very different stories about what that price really meant.

On the upbeat side, the bullish case argued that accelerated store openings, better automation and centralized inventory could lift efficiency, with a Fair Value of ZAR46.2. This was the price implied if those optimistic assumptions played out. That narrative leaned on Dis-Chem capturing demand from an aging population and chronic disease, with digital tools and clinics helping to deepen recurring prescription revenue.

The cautious view put more weight on rising salaries, rental inflation and electricity costs, with a Fair Value of ZAR29. This was the price suggested if these cost pressures and saturation risks were front of mind. Bears focused on the chance that doubling store openings into already dense areas might squeeze margins and weaken same-store sales if new outlets simply pulled volume from existing pharmacies.

What The Dis-Chem Pharmacies Results Put To The Test

The clearest datapoint was Dis-Chem Pharmacies lifting total revenue from ZAR19,609.744m in H2 2025 to ZAR21,551.492m in H2 2026, which spoke to the optimistic demand story. Profit told a different tale, with net income and net margin sliding to ZAR345.776m and 1.6% from ZAR602.1m and 3.1%. The evidence cut both ways.

The lesson is simple. When you hear a profit story built on operating leverage, test it against net margin in later reports and see whether higher sales actually turn into richer profitability.

What You Would Be Paying For In Dis-Chem Pharmacies Today

Dis-Chem Pharmacies now trades at ZAR27.28, after a share price that declined 22.5% from the start of the year. The selected Narrative’s Fair Value sits above the current price, based on a case that leans on expansion, automation and data heavy execution rather than just more stores.

At this level, you would be asking whether that drop is a warning about store saturation and cost pressure, or whether it reflects skepticism that Dis-Chem can translate rollout, clinics and digital health into faster margin repair than recent results suggest.

"Analysts broadly agree that Dis-Chem's property rollout will drive incremental revenue, but they may be underestimating the impact of the accelerated and analytically-led expansion, which is set to nearly double annual store openings and penetrate underrepresented, high-growth regions. This level of scale could support higher revenue and stronger operating leverage."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Which Company Could Surprise You Next?

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 24% below our estimate - expands higher profile boutiques and upgrades mobile and ecommerce to deepen shopper engagement.
• Company 2 - 25% below our estimate - targets maintenance customers more aggressively by enlarging its sales force to win recurring contracts.
• Company 3 - 37% below our estimate - builds AI driven hiring and services platforms that tie fees directly to transaction volumes.

That is three of the list. See every one of the 202 solid balance sheet companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com